Boehringer Ingelheim

Boehringer Ingelheim collaborates with Presidio Pharmaceuticals

Monday, September 16, 2013 03:12 PM

Boehringer Ingelheim has completed patient enrollment for a phase IIa clinical trial (NCT01859962) investigating a new interferon-free, all-oral, direct-acting antiviral (DAA) combination treatment for patients with genotype-1a chronic hepatitis C virus (HCV) infection. This trial is conducted in collaboration with Presidio Pharmaceuticals and evaluates Boehringer Ingelheim’s investigational compounds, the protease inhibitor faldaprevir (BI 201335) and non-nucleoside NS5B polymerase inhibitor, deleobuvir (BI 207127), in combination with Presidio’s investigational pan-genotypic NS5A inhibitor, PPI-668, with and without ribavirin.

More... »

Boehringer Ingelheim Chemicals to close Virginia facility

Friday, August 16, 2013 01:49 PM

Boehringer Ingelheim Chemicals will close its Petersburg, Va. plant at the end of 2014. The facility will continue normal operations through the remainder of 2013 and phase out operations the following year. The closure will impact 240 employees through a multi-stage process beginning December.

More... »

Boehringer, Lilly enroll first patient in type 2 diabetes trial

Friday, August 9, 2013 02:07 PM

Boehringer Ingelheim Pharmaceuticals and Eli Lilly have announced enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for linagliptin (tradjenta) tablets.

More... »

Healthrageous, United BioSource, Boehringer Ingelheim launch SMART digital diabetes study

Friday, July 19, 2013 01:30 PM

Healthrageous, a digital health management company, and pharmaceutical company Boehringer Ingelheim have launched the SMART study with United BioSource (UBC) to evaluate a digital technology enabled self-management solution to potentially improve the health status of people with type 2 diabetes. The goal of the solution is to leverage technology in a way that makes the personalized journey of self-managing diabetes easier for patients to self-manage their disease.

More... »

BI, EFSD commit $3.3 million to European diabetes research initiatives

Friday, July 19, 2013 01:27 PM

The Boehringer Ingelheim (BI) and European Foundation for the Study of Diabetes (EFSD) partnership has announced the recipients of its European-wide funding initiative targeted at diabetes research. Totaling $3.3 million, these are the first grants to be awarded as part of the EFSD/Boehringer Ingelheim European Diabetes Research Programs, which aim to stimulate and accelerate European research in diabetes.

More... »

Athera, Boehringer Ingelheim enter option agreement on novel therapy

Thursday, June 20, 2013 10:00 AM

Athera Biotechnologies has entered into an option agreement with Boehringer Ingelheim International on a novel preclinical antibody program, which grants Boehringer Ingelheim an exclusive option to acquire the entire program.

More... »

Boehringer Ingelheim, Zhangjiang to open biopharmaceuticals facility in China

Tuesday, June 11, 2013 10:00 AM

Boehringer Ingelheim and Zhangjiang Biotech & Pharmaceutical Base Developmentof Pudong, Shanghai have allied to build a cGMP biopharmaceuticals facility. The site will provide development and clinical services to Chinese and multi-national customers. It will utilize mammalian cell culture technology.

More... »

Boehringer Ingelheim selects ChemAxon’s chemistry software

Friday, February 15, 2013 12:11 PM

Boehringer Ingelheim has chosen ChemAxon, a provider of chemistry software solutions and consulting services for life science research, as its provider for a chemistry software platform for multiple applications across R&D, supporting in-house activities and work with external collaboration partners.

More... »

Lilly reassumes sole worldwide rights for novel basal insulin analog

Monday, January 7, 2013 10:55 AM

Global pharmaceutical company Eli Lilly and Boehringer Ingelheim, a Germany-based pharmaceutical company, will adjust the scope of their diabetes alliance with respect to LY2605541, Lilly's investigational novel basal insulin analog, with Lilly reassuming sole worldwide development and commercialization rights to LY2605541.

More... »

Boehringer Ingelheim launches Hep C online resource

Tuesday, November 13, 2012 01:39 PM

Boehringer Ingelheim has launched HepCRedefined.com, an online portal to help improve the lives of those living with the hepatitis C virus (HCV) through education, information and understanding. The portal aims to redefine the HCV journey by providing downloadable and shareable resources to healthcare providers, advocates, caregivers and patients.

More... »